To assess the potential relevance of CCL2 in disease progression and in the response to BRAFi treatment in melanoma patients, we studied tumor samples and plasma in a set of cases with a follow-up of 2 y after the beginning of treatment with vemurafenib [26]. This evidence concerns the gene CCL2 and melanoma.